PBLS

Parabilis Medicines, Inc.

Nasdaq · CIK 0001657677
$27.26 -10.06% $3.2B
High Impact Filing (7/10)
Vol
Market Cap$3.2B
Cap SizeMid Cap
SEC Reports12
Press Releases1
Exchange Nasdaq·CIK 0001657677·Prev Close $30.31

Recent Activity

Jun 11, 2026 SEC
Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regeneron at a 10% discoun
8-K — Impact 6/10
Jun 11, 2026 offering
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p align="left">CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nas
Jun 11, 2026 Insider
Flynn James E acquired 122,990 shares
10%+ Owner
Jun 11, 2026 Insider
Flynn James E disposed of 166,070 shares
10%+ Owner
Jun 11, 2026 Insider
Flynn James E disposed of 143,650 shares
10%+ Owner
Jun 10, 2026 SEC
Parabilis Medicines priced its IPO of 33,500,000 shares at $20.00/share, raising approximately $623.1 million in gross p
424B4 — Impact 7/10
Jun 10, 2026 SEC
Parabilis Medicines' S-1 registration statement (File No. 333-296032) became effective on June 9, 2026, clearing the way
EFFECT — Impact 7/10
Jun 10, 2026 Press
Parabilis Medicines priced its upsized IPO of 33.5M shares at $20.00/share, expecting gross proceeds of $670M, plus a co
Impact 7/10

Latest Reports

MIXED 8-K 6/10
Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regeneron at a 10% discoun
Jun 11, 2026
BULLISH 424B4 7/10
Parabilis Medicines priced its IPO of 33,500,000 shares at $20.00/share, raising approximately $623.1 million in gross p
Jun 10, 2026
BULLISH Press 7/10
Parabilis Medicines priced its upsized IPO of 33.5M shares at $20.00/share, expecting gross proceeds of $670M, plus a co
Jun 10, 2026

Recent Insider Trades

DateInsiderTypeValue
Jun 11, 2026Flynn JamesC$0.00
Jun 11, 2026Flynn JamesC$0.00
Jun 11, 2026Flynn JamesC$0.00
Jun 11, 2026Flynn JamesC$0.00
Jun 11, 2026Flynn JamesC$0.00
∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

9 unique insiders with 13 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 11, 2026Flynn James E10%+ OwnerCONVERT122,990——
Jun 11, 2026Flynn James E10%+ OwnerCONVERT166,070——
Jun 11, 2026Flynn James E10%+ OwnerCONVERT143,650——
Jun 11, 2026Flynn James E10%+ OwnerCONVERT246,732——
Jun 11, 2026Flynn James E10%+ OwnerCONVERT464,550——
Jun 9, 2026SEBULSKY ALANDirectorAWARD39,792——
Jun 9, 2026Klausner RichardDirectorAWARD20,215——
Jun 9, 2026FITZGERALD EDWARD MDirectorAWARD20,215——
Jun 9, 2026Simson JakeDirectorAWARD20,215——
Jun 9, 2026Yeshwant KrishnaDirectorAWARD20,215——
Jun 9, 2026Borisy AlexisDirectorAWARD20,215——
Jun 9, 2026Weber BarbaraDirectorAWARD20,215——
Jun 9, 2026RA CAPITAL MANAGEMENT, L.P.DirectorAWARD20,215——
12 SEC filing reports analyzed. Sentiment: 5 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 4.3/10.
MIXED 8-K 6/10
Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regene
Jun 11, 2026
BULLISH 424B4 7/10
Parabilis Medicines priced its IPO of 33,500,000 shares at $20.00/share, raising approximately $623.
Jun 10, 2026
BULLISH EFFECT 7/10
Parabilis Medicines' S-1 registration statement (File No. 333-296032) became effective on June 9, 20
Jun 10, 2026
NEUTRAL 3 2/10
Mathai Mammen, President & CEO of Parabilis Medicines, filed a Form 3 initial statement of beneficia
Jun 10, 2026
NEUTRAL 3 1/10
Alan Sebulsky filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines, Inc
Jun 10, 2026
NEUTRAL 3 1/10
Krishna Yeshwant filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines,
Jun 10, 2026
NEUTRAL 3 2/10
Richard Klausner filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines,
Jun 10, 2026
NEUTRAL 3 2/10
Edward M. Fitzgerald filed a Form 3 initial statement of beneficial ownership with the SEC, disclosi
Jun 10, 2026
NEUTRAL 3 2/10
Alexis Borisy filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines, Inc
Jun 10, 2026
BULLISH S-1/A 7/10
Parabilis Medicines, a clinical-stage biopharmaceutical company developing Helicon therapeutics for
Jun 9, 2026
BULLISH S-1/A 7/10
Parabilis Medicines, a clinical-stage biopharmaceutical company developing Helicon therapeutics for
Jun 4, 2026
BULLISH S-1/A 7/10
Parabilis Medicines is a pre-IPO biotech filing an amended S-1 registration statement, disclosing a
May 27, 2026
BULLISH 7/10
Parabilis Medicines priced its upsized IPO of 33.5M shares at $20.00/share, expecting gross proceeds
Jun 10, 2026

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
 $0.00 $0.00 $0.00 — — — $0.0B — —
Next Q
 $0.00 $0.00 $0.00 — — — $0.0B — —
Current FY
 $0.00 $0.00 $0.00 — — — $0.0B — —
Next FY
 $0.00 $0.00 $0.00 — — — $0.0B — —
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 11, 2026
offering
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p align="left">CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biophar
Jun 10, 2026
fda
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
<p align="left">CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biophar